TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19683392

Group type: EXPERIMENTAL
Intervention: Intrathecal glycine (ITG) treatment for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 19
Study: 16893698

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 106
Study: 12542733

Group type: EXPERIMENTAL
Intervention: IVIG-N
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sandoglobulin
Number of subjects: 63
Study: 10701032

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron 100 micrograms/kg at induction (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron 100 micrograms/kg at the end of surgery (Group 2)
Number of subjects: 120
Study: 9432300

Group type: EXPERIMENTAL
Intervention: Hypolipidemic drugs
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Short duration of neuro‐ and psychasthenic forms of cerebral artery atherosclerosis
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 3
Study: 1589702

Group type: EXPERIMENTAL
Intervention: Al(OH)3 and Mg(OH)2 (preparation A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: AlPO4 (preparation B)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Antacid or placebo medication
Number of subjects: 18
Study: 3910604

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (1 g or 0.5 g every 12 h, i.v. or i.m. for 10 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cefotaxime (dosage not specified)
Number of subjects: 80
Study: 29752869

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of non-HLA matched, ABO matched, unrelated allogeneic umbilical cord blood (UCB)
Number of subjects: 10
Study: 26335028

Group type: EXPERIMENTAL
Intervention: 80% mTSC, 80 Hz, 400 μs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 60% mTSC, 80 Hz, 400 μs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 80% mTSC, 20 Hz, 400 μs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 60% mTSC, 20 Hz, 400 μs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 80% mTSC, 80 Hz, 150 μs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 60% mTSC, 80 Hz, 150 μs
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 13
Study: 25293388

Group type: EXPERIMENTAL
Intervention: Echium oil (7.5 ml b.i.d., 235 mg/ml α-linolenic acid + 95 mg/ml stearidonic acid + 79 mg/ml γ-linolenic acid)
Number of subjects: 91

Group type: COMPARATOR
Intervention: n-3 FA deficient sunflower oil high oleic (7.5 ml b.i.d.)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Echium oil
Number of subjects: 91

Group type: COMPARATOR
Intervention: n-3 FA deficient sunflower oil high oleic
Number of subjects: 91
Study: 22913889

Group type: EXPERIMENTAL
Intervention: Metformin plus colesevelam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin plus placebo
Number of subjects: 0
Study: 19809806

Group type: EXPERIMENTAL
Intervention: Biplanar osteotomy with a short spacer plate (group 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Biplanar osteotomy with a long and rigid plate fixator (group 2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Uniplanar osteotomy with a short spacer plate (group 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Uniplanar osteotomy with a long and rigid plate fixator (group 2)
Number of subjects: 24
Study: 18005842

Group type: EXPERIMENTAL
Intervention: Transbond Plus SEP with Transbond XT adhesive
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ideal 1 SEP with Ideal 1 adhesive
Number of subjects: 36
Study: 16052193

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg/day
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 12382384

Group type: EXPERIMENTAL
Intervention: 67% nitrous oxide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sevoflurane alone (control group)
Number of subjects: 30
Study: 12904156

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other antimalaria drugs
Number of subjects: 0
Study: 9504513

Group type: EXPERIMENTAL
Intervention: Active management (prophylactic oxytocic within 2 min of baby's birth, immediate cutting and clamping of the cord, delivery of placenta by controlled cord traction or maternal effort)
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Expectant management (no prophylactic oxytocic, no cord clamping until pulsation ceased, delivery of placenta by maternal effort)
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Active management
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1512
Study: 7846197

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Quitters who returned to previous smoking level
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Quitters who remained abstinent or smoked occasionally
Number of subjects: 148

Group type: COMPARATOR
Intervention: Nonsmoking group (control)
Number of subjects: 148
Study: 30317339

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 76

Group type: COMPARATOR
Intervention: Febuxostat
Number of subjects: 76
Study: 27941492

Group type: EXPERIMENTAL
Intervention: 10 sets of 10 repetitions
Number of subjects: 19

Group type: COMPARATOR
Intervention: 5 sets of 10 repetitions
Number of subjects: 19
Study: 26446416

Group type: EXPERIMENTAL
Intervention: Diathermy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 130
Study: 23289728

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/day
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: High baseline AGEs levels
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: sRAGE levels
Number of subjects: 208
Study: 21842188

Group type: EXPERIMENTAL
Intervention: Olfactory bulb volume measurements and olfactory function tests (odor threshold, odor discrimination, odor identification)
Number of subjects: 87
Study: 17947301

Group type: EXPERIMENTAL
Intervention: Initial combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Any treatment strategy (without treatment adjustments)
Number of subjects: 0
Study: 17048425

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 276

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 276
Study: 12952249

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11129008

Group type: EXPERIMENTAL
Intervention: 7-day course of oral prednisolone (10 mg/day for ages 5-11, 0.5 mg/kg for ages 12 and older)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9044556

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron (single dose)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron (repetitive doses)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 16 mg ondansetron (single dose)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 51
Study: 1576067

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg as a single dose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg four times daily for 8 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg four times daily for 27 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flurbiprofen administration
Number of subjects: 8
Study: 28574182

Group type: COMPARATOR
Intervention: Standard bolus
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination bolus 70/30
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination bolus 60/40
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination bolus 30/70
Number of subjects: 19
Study: 26223246

Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Comparison Health and Wellness (control)
Number of subjects: 150
Study: 23111004

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) hypocaloric diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: High Glycemic Index (HGI) hypocaloric diet
Number of subjects: 40
Study: 21968663

Group type: EXPERIMENTAL
Intervention: Sertaconazole nitrate 2% cream, once daily for four weeks
Number of subjects: 32
Study: 19765006

Group type: EXPERIMENTAL
Intervention: Formula supplemented with docosahexaenoic acid and arachidonic acid (LCPUFA)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 229
Study: 16456211

Group type: EXPERIMENTAL
Intervention: Educational interventions promoting evidence-based supply of non-prescription medicines
Number of subjects: 60
Study: 15275801

Group type: EXPERIMENTAL
Intervention: Parenteral parecoxib sodium followed by oral valdecoxib
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 191
Study: 11439738

Group type: EXPERIMENTAL
Intervention: Dialysate conductivity adjusted to be 0.3 mS/cm more than the mean during the run-in period (B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dialysate conductivity adjusted to be 0.3 mS/cm less than the mean during the run-in period (C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard PFD treatment (A)
Number of subjects: 0
Study: 9215016

Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg h-1
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bupivacaine 1 mg h-1
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bupivacaine 1 mg h-1 combined with morphine 8 micrograms h-1
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 55
Study: 7955969

Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients
Number of subjects: 507
Study: 2890709

Group type: EXPERIMENTAL
Intervention: Intracerebroventricular (ICV) cholinergic drug infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30127137

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 100
Study: 27505702

Group type: EXPERIMENTAL
Intervention: Responsive stimulation intervention
Number of subjects: 1302
Study: 24456988

Group type: EXPERIMENTAL
Intervention: Blended iterative reconstruction (iDOSE 1‐4)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Filtered back projection
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: iDOSE levels (1-4)
Number of subjects: 44
Study: 21848545

Group type: EXPERIMENTAL
Intervention: Removable dental prostheses (RDP)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Fixed dental prostheses (FDP)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Control group (no dental treatment)
Number of subjects: 307
Study: 20398111

Group type: EXPERIMENTAL
Intervention: Tone-emitting otoscope
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: Questionnaire about hearing handicap
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: Combination of both tools
Number of subjects: 2305

Group type: COMPARATOR
Intervention: No screening (Control)
Number of subjects: 2305
Study: 18466043

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3, 6, 9, 12, or 15 mg daily)
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1326
Study: 15665343

Group type: EXPERIMENTAL
Intervention: Atropine eye drops (once daily for 2 years)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo eye drops (once daily for 2 years)
Number of subjects: 105
Study: 12947054

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 day 1 plus gemcitabine 1,250 mg/m2 days 1 and 8, every 3 weeks for six cycles (CG)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 day 1 plus gemcitabine 1,000 mg/m2 and vinorelbine 25 mg/m2 days 1 and 8, every 3 weeks for six cycles (CGV)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Gemcitabine 1,000 mg/m2 plus vinorelbine 30 mg/m2 days 1 and 8, every 3 weeks for three cycles, followed by vinorelbine 30 mg/m2 days 1 and 8 plus ifosfamide 3 g/m2 day 1, every 3 weeks for three cycles (GV-VI)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 day 1 plus gemcitabine 1,250 mg/m2 days 1 and 8 (CG)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 day 1 plus gemcitabine 1,000 mg/m2 and vinorelbine 25 mg/m2 days 1 and 8 (CGV)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Gemcitabine 1,000 mg/m2 plus vinorelbine 30 mg/m2 days 1 and 8 (GV-VI)
Number of subjects: 557
Study: 10446879

Group type: EXPERIMENTAL
Intervention: Malignant non-Hodgkin's lymphoma (MNHL) patients
Number of subjects: 33
Study: 8690822

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 0
Study: 6646956

Group type: EXPERIMENTAL
Intervention: Directional bias in visual perception tasks (dot-asynchrony judgments and letter recall)
Number of subjects: 65
Study: 31474396

Group type: COMPARATOR
Intervention: Supervised exercise program
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Home exercise program
Number of subjects: 108
Study: 28834836

Group type: COMPARATOR
Intervention: Conservative treatment group (n = 40)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Operative treatment group (n = 32)
Number of subjects: 72
Study: 25714415

Group type: EXPERIMENTAL
Intervention: Lidocaine injection plus physiotherapy (INJPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 0
Study: 23315603

Group type: EXPERIMENTAL
Intervention: Structured behavioral group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 71

Group type: COMPARATOR
Intervention: One-to-one education
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Younger behavioral group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Younger control group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Self-care interventions
Number of subjects: 71
Study: 22082443

Group type: EXPERIMENTAL
Intervention: 1500 iu hCG and a single dose of 50 mg dexamethasone
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (110 cycles without treatment)
Number of subjects: 152
Study: 19012048

Group type: EXPERIMENTAL
Intervention: Capsicum oleous nasal spray, 4 microg/puff, three times a day for 3 consecutive days
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Capsicum oleous nasal spray (1 microg/puff and 2 microg/puff)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 17448621

Group type: EXPERIMENTAL
Intervention: Doctor-based patient education (group A)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Computer-based patient education (group B)
Number of subjects: 113
Study: 12644418

Group type: EXPERIMENTAL
Intervention: Propofol induction and halothane/nitrous oxide maintenance
Number of subjects: 322

Group type: COMPARATOR
Intervention: Sevoflurane/nitrous oxide
Number of subjects: 322
Study: 11062569

Group type: EXPERIMENTAL
Intervention: Dynamic outrigger splint
Number of subjects: 100

Group type: COMPARATOR
Intervention: Palmar blocking splint
Number of subjects: 100
Study: 9059063

Group type: EXPERIMENTAL
Intervention: Remission induction therapy (AVC) with terarubicin (THP‐ADR), vincristine, and continuous infusion of cytosine arabinoside (Ara C) for 32 or 48 weeks.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: VP16 + high dose Ara C used sequentially for 32 or 48 weeks.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treatment period of 32 weeks vs 48 weeks.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ANLL‐9205 protocol.
Number of subjects: 45
Study: 8458096

Group type: EXPERIMENTAL
Intervention: Standard GH treatment (20 units/m2/week)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High dose GH treatment (40 units/m2/week)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both GH treatment groups
Number of subjects: 29
Study: 3724995

Group type: EXPERIMENTAL
Intervention: Long-term lithium treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo treatment (6 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Reinstituted lithium treatment (6 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Continuous lithium medication (replication study)
Number of subjects: 16
Study: 30836801

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 10 mg twice weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 25 mg twice weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study: 29139599

Group type: EXPERIMENTAL
Intervention: Multifactorial fall-prevention program
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Positive Attitudes to Falls-Related Interventions Scale (AFRIS) scores
Number of subjects: 85
Study: 26294761

Group type: EXPERIMENTAL
Intervention: 'Pink eye' label
Number of subjects: 0

Group type: COMPARATOR
Intervention: 'Eye infection' label
Number of subjects: 0
Study: 24170757

Group type: EXPERIMENTAL
Intervention: Self-titration of bolus insulin glulisine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician titration of bolus insulin glulisine
Number of subjects: 0
Study: 22436405

Group type: EXPERIMENTAL
Intervention: Falls-related self-efficacy assessed by the activities-specific balance confidence (ABC) scale
Number of subjects: 79
Study: 20137090

Group type: EXPERIMENTAL
Intervention: Tight blood glucose control using insulin by intravenous infusion titrated to maintain BG between 4 and 7.0 mmol/l.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard current approach to blood glucose management (Control group).
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Tight blood glucose control (I) and Standard current approach (C).
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Tight blood glucose control (I).
Number of subjects: 1000
Study: 18393319

Group type: EXPERIMENTAL
Intervention: 600 microg/kg rFVIIa (200 + 4x 100 microg/kg)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 300 microg/kg rFVIIa (200 + 100 microg/kg)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 15809563

Group type: EXPERIMENTAL
Intervention: Lace-up style ankle support
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Adhesive tape and semirigid style ankle support
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no ankle support)
Number of subjects: 93
Study: 12088969

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of bupivacaine and ropivacaine
Number of subjects: 60
Study: 10754428

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8701046

Group type: EXPERIMENTAL
Intervention: SPf66 vaccine
Number of subjects: 0
Study: 1887746

Group type: EXPERIMENTAL
Intervention: Atropine (120 micrograms)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (50 micrograms)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atropine (720 micrograms)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (300 micrograms)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7167734

Group type: EXPERIMENTAL
Intervention: 25 mg/day of trimipramine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 30854569

Group type: EXPERIMENTAL
Intervention: Blood transfusion (135 women)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Previous Caesarean section
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Anterior placenta praevia
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Major placenta praevia
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Preoperative bleeding of more than 250 mL
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Preoperative anaemia
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Emergency Caesarean section
Number of subjects: 405
Study: 27756097

Group type: EXPERIMENTAL
Intervention: Multiple emulsion (ME1) containing Ascorbyl Palmitate (AP) and Sodium Ascorbyl Phosphate (SAP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (without AP and SAP)
Number of subjects: 11
Study: 26764966

Group type: EXPERIMENTAL
Intervention: CAF + bioactive glass putty
Number of subjects: 10

Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 10
Study: 23185084

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 4 x 4 minutes at 85-95% of peak heart rate, three times per week for eight weeks, repeated three times throughout one year
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 52
Study: 22847212

Group type: EXPERIMENTAL
Intervention: Anti-TNF experienced (EXP)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Anti-TNF naïve (NAÏVE)
Number of subjects: 300
Study: 20682154

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (n = 35)
Number of subjects: 68

Group type: COMPARATOR
Intervention: General anesthesia (n = 33)
Number of subjects: 68
Study: 17548727

Group type: COMPARATOR
Intervention: Noncotinine group (nondetectable cotinine)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Low cotinine group (cotinine between 0.2 and 1.6 ng/mL)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Top decile cotinine group (cotinine ≥ 1.7 ng/mL)
Number of subjects: 402
Study: 15602499

Group type: EXPERIMENTAL
Intervention: 15 mg gaboxadol hydrochloride
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11966623

Group type: COMPARATOR
Intervention: Standard dose (81 mg) of intravesical bacille Calmette-Guérin (BCG)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Reduced dose (27 mg) of intravesical bacille Calmette-Guérin (BCG)
Number of subjects: 500
Study: 9818881

Group type: EXPERIMENTAL
Intervention: Oral branched-chain amino acids (BCAAs) at a dosage of 77 mg/kg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control noncaloric beverage
Number of subjects: 6